1-(furan-2-methyl) pyrrolidine, as an ST2 inhibitor, releases IL-33 from sST2 and may regulate the T cell response to treat GVHD, thereby achieving therapeutic effects. This evidence concerns the gene IL33 and graft versus host disease.